Stefanie Hieke-Schulz - Roche Pharm AG

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 12 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Conditional Survival to Assess Prognosis in Patients with Chronic Lymphocytic Leukemia

Pascal Schlosser,Annett Schiwitza, Jonas Klaus,Stefanie Hieke-Schulz,Katarzyna Szarc vel Szic,Justus Duyster,Martin Trepel,Katja Zirlik,Martin Schumacher,Rainer Claus

ANNALS OF HEMATOLOGYno. 5 (2024): 1613-1622

引用0浏览0WOS引用

Real-world effectiveness of ocrelizumab in patients with primary progressive multiple sclerosis grouped by EDSS at baseline - a CONFIDENCE study interim analysis

Sven Meuth,Mathias Buttmann,Martin Weber,Sandra Bluemich,Petra Dirks,Julius Eggebrecht,Stefanie Hieke-Schulz,Jost Leemhuis,Tjalf Ziemssen

MULTIPLE SCLEROSIS JOURNAL (2023): 376-377

引用0浏览0引用

Specific unmet medical needs in the care of patients with relapsing multiple sclerosis: Final results from the PROFILE RMS study

Iris-Katharina Penner,Herbert Schreiber, Tanja Maier,Jost Leemhuis,Stefanie Hieke-Schulz,Tjalf Ziemssen

MULTIPLE SCLEROSIS JOURNAL (2023): 636-637

引用0浏览0引用

Real-world safety data from up to 4.5 years of ocrelizumab in relapsing and primary progressive multiple sclerosis - a CONFIDENCE interim analysis

Martin Weber,Mathias Buttmann,Sven Meuth,Sandra Bluemich,Petra Dirks,Julius Eggebrecht,Stefanie Hieke-Schulz,Jost Leemhuis,Tjalf Ziemssen

MULTIPLE SCLEROSIS JOURNAL (2023): 373-374

引用0浏览0引用

Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated with Ocrelizumab: First Insights from the CONFIDENCE Study

Martin S. Weber,Mathias Buttmann,Sven G. Meuth,Petra Dirks,Erwan Muros-Le Rouzic,Julius C. Eggebrecht,Stefanie Hieke-Schulz,Jost Leemhuis,Tjalf Ziemssen

Frontiers in neurology（2022）

引用3浏览0WOS引用

A Multicentre Analytical Comparison Study of Inter‐reader and Inter‐assay Agreement of Four Programmed Death‐ligand 1 Immunohistochemistry Assays for Scoring in Triple‐negative Breast Cancer

Aurelia Noske,Johannes U. Ammann,Daniel-Christoph Wagner,Carsten Denkert,Annette Lebeau,Peter Sinn,Hans-Heinrich Kreipe,Ulrich Sommer,Gustavo Baretton,Katja Steiger,Marion Kiechle,Stefanie Hieke-Schulz,Mike Flores,Wilfried Roth,Wilko Weichert

HISTOPATHOLOGY（2021）

引用25浏览0WOS引用

Ocrelizumab Real-World Safety in the Treatment of Multiple Sclerosis (MS): Differences Between Investigator-Reported and Patient-Reported Safety

Jost Leemhuis,Richard Hughes,Julius Eggebrecht,Petra Dirks,Stefanie Hieke-Schulz, Klara Keine,Tjalf Ziemssen

NEUROLOGY（2020）

引用0浏览0引用

Design of a Non-Interventional Post-Marketing Study to Assess the Long-Term Safety and Effectiveness of Ocrelizumab in German Real World Multiple Sclerosis Cohorts – the CONFIDENCE Study Protocol

Petra Dirks,Vera Zingler,Jost Leemhuis, Heike Berthold,Stefanie Hieke-Schulz,David Wormser,Tjalf Ziemssen

BMC neurology（2020）

引用20浏览0WOS引用

Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma

Ulrich Sommer,Markus Eckstein,Johannes Ammann,Till Braunschweig,Stephan Macher-Goeppinger,Kristina Schwamborn,Stefanie Hieke-Schulz,Greg Harlow,Mike Flores,Bernd Wullich,Manfred Wirth,Wilfried Roth,Ruth Knuechel,Wilko Weichert,Gustavo Baretton,Arndt Hartmann

Clinical Genitourinary Cancer（2020）

引用8浏览0WOS引用

Reasons to Switch: a Noninterventional Study Evaluating Immunotherapy Switches in a Large German Multicentre Cohort of Patients with Relapsing-Remitting Multiple Sclerosis

Mathias Maeurer,Klaus Tiel-Wilck, Eckard Oehm,Nils Richter, Michael Springer,Patrick Oschmann,Arndt Manzel,Stefanie Hieke-Schulz,Vera Zingler, Julia A. Kandenwein,Tjalf Ziemssen,Ralf A. Linker

Therapeutic Advances in Neurological Disorders（2019）

引用19浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn